Revenue segments as reported by the company.

Companion Animal

Livestock

Contract Manufacturing & Human Health

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Interest expense

Other (income)/deductions–net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zoetis

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The firm operates through the following segments: United States & International. Its products include vaccines, parasiticides, anti-infectives, dermatology products, medicated feed additives, animal health diagnostics, and other pharmaceutical products for both companion animal and livestock customers. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zoetis reports robust 2022 results, eyes growth in key markets

Zoetis delivered strong financial performance in 2022 and projects continued growth in 2023. The company's investments in R&D, CapEx, and customer engagement strategies position it well for future competition. Challenges from inflation, competition, and supply chain issues require careful navigation, but opportunities in key growth areas offer potential for sustained success.

Zoetis reports solid Q1 results, reaffirms full-year guidance

Zoetis delivered solid Q1 results despite challenges in certain segments. The company remains optimistic about future growth opportunities, supported by upcoming product launches and strategic investments. Investor Day will provide detailed insights into Zoetis' growth strategy and innovation pipeline.

Zoetis reports robust Q2 earnings, eyes global market expansion

Zoetis delivered strong financial results in Q2 2023, with expectations of continued growth in operational revenue and adjusted net income for the full year. The company remains focused on driving revenue growth through industry tailwinds and innovation over the next few years.

Zoetis reports robust Q3 performance and anticipates accelerated growth

Zoetis' Q3 2023 performance reflects strong revenue and income growth, supported by successful product launches and a robust diagnostics portfolio.
While facing challenges from upcoming competition and margin pressures, the company remains confident in its growth prospects for 2023 and 2024.
Opportunities lie in accelerated growth driven by key products, macro trends in animal health, and ongoing investments in innovation and cost management.
Overall, Zoetis' strategic strengths position it well to navigate challenges and capitalize on opportunities for sustained growth and value creation.

Zoetis reports robust 2023 results and sets sights on international growth

Zoetis delivered strong financial performance in 2023, driven by innovative products and operational growth across portfolios. The company is well-positioned for continued growth in 2024, focusing on innovation, market leadership, and addressing challenges like currency dynamics and capacity constraints. Opportunities lie in international markets, DTC initiatives, and sustained revenue growth.

Zoetis excels in Q1 with double-digit growth and strategic focus

Zoetis' Q1 performance reflects strong revenue and income growth, driven by successful product launches and market leadership. The company's focus on innovation, quality, and strategic divestments positions it well for future growth. Challenges in livestock and competition require strategic adaptation, while opportunities in product growth and market expansion offer promising avenues for development.

Zoetis excels in Q2 2024, raises guidance and announces buyback

Zoetis' Q2 2024 performance highlights its strong market position, driven by innovative products and strategic initiatives. While challenges exist in the competitive landscape, the company's focus on customer-centric innovation and financial strength position it well for future growth. With raised guidance and shareholder value initiatives, Zoetis is poised for continued success in the animal health industry.

Zoetis reports strong Q3 earnings and eyes sustained growth

Zoetis delivered robust operational growth in Q3 2024, driven by strong performance in key segments and products, leading to a revised full year guidance and confidence in future prospects.
Despite potential challenges in navigating a dynamic landscape and supply chain efficiency, Zoetis remains well-positioned to capitalize on opportunities for growth in 2025 through innovation and market expansion.
With a focus on sustained above-industry average growth, Zoetis' strategic strengths in key franchises and market positioning reinforce their leadership in the animal health industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

BANGKOK--(BUSINESS WIRE)-- #BPTW4Thailand--Zoetis Thailand, an affiliate of the global animal health company dedicated to supporting customers and their businesses in ever better ways, has recently been recognized as one of the best places to work in Thailand for 2021. During the assessment, the company received outstanding scores across several aspects of their workplace going above and beyond the norm to create an enjoyable and meaningful work environment. In this very unusual year, we learned again that empl

Zoetis Earns the Best Place To Work Certification in Thailand for 2021

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #annualmeeting--Zoetis announced the results of shareholder voting at its 2021 Annual Meeting of Shareholders and provided details on its third quarter 2021 dividend.

Zoetis Announces Results of Its Annual Meeting of Shareholders; Board Declares Third Quarter 2021 Dividend

Boqii Holding

Chewy

Freshpet

PetIQ

PetMed Express

Trupanion

Petco Health and Wellness

While the market has taken a beating over recent days, pullbacks are the mother's milk of effective investment strategies, and shrewd market participants will already have a growing shopping list on hand. With that in mind, one area that may deserve special attention and offer outsized potential ahead is the pet care space.

Growth Stock Spotlight: Acquisition Pits CSOC as Fresh Option in Booming Petcare Market

Booz Allen Hamilton Hld

Best Buy

Domino's Pizza

Johnson Outdoors

Mastercard

Medifast

MarketAxess Holdings

MSCI

Old Dominion Freight Line

Universal Display

Primerica

Sherwin-Williams

S&P Global

T. Rowe Price Group

Tractor Supply

Texas Instruments

Fast growing dividends may have low initial yields but will grow rapidly over time.

Boost Your Future Income With These Fast Growing Dividends

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. announced leadership changes that will accelerate its long-term growth strategy in key markets and add new talent to its executive team.

Zoetis Announces Appointment of Glenn David as Group President and Wetteny Joseph as Executive Vice President and Chief Financial Officer

Amneal Pharmaceuticals

AMRX vs. ZTS: Which Stock Is the Better Value Option?

AMRX or ZTS: Which Is the Better Value Stock Right Now?

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Zoetis (ZTS) Just Overtook the 20-Day Moving Average

Zoetis stock fell 3.7% on Thursday despite stronger-than-expected Q1 results and a raised 2021 outlook, including Net Income growing 12-14%. In Q1, Zoetis revenues grew 21%, led by Companion Animals up 34% but with Livestock up 17% in International; Net Income grew 34%.

Zoetis: 3.7% Dip Despite Strong Q1 And Raised 2021 Outlook

Bullish spending on pet health helped Zoetis easily beat first-quarter expectations. But Zoetis stock crumbled after the open.

Fido's Drugmaker Slammed Despite Easy Beat On Growing Pet Sales

Zoetis Inc. (ZTS) CEO Kristin Peck on Q1 2021 Results - Earnings Call Transcript

Zoetis (ZTS) delivered earnings and revenue surprises of 21.15% and 7.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) Q1 Earnings and Revenues Beat Estimates

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #earnings--Zoetis reports first quarter 2021 results.

Zoetis Announces First Quarter 2021 Results

Amgen

Amazon

Cooper Companies

Dollar General

McCormick

NextEra Energy

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

2020 shows that investors need to be prepared for anything. These eight retirement stocks can do precisely that.

8 Retirement Stocks to Buy for Any Market Conditions

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #earnings--Zoetis will report Q1 2021 financial results on May 6th.

Zoetis to Host Webcast and Conference Call on First Quarter 2021 Financial Results

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock?

Zoetis (ZTS) Down 7.5% Since Last Earnings Report: Can It Rebound?

Zoetis has proven to investors that the pharmaceutical apple doesn't fall far from the tree.

Why Zoetis Is the Pfizer of Animal Healthcare

We upgrade Zoetis to Buy after a 14% price decline, means this multi-year compounder once again offers a low-teens annualized return.

Zoetis: Multi-Year Compounder On Sale Again After 14% Correction

This leader in animal healthcare has shown strong financial performance through the years.

Is Zoetis Still a Buy With Its Stock Near All-Time Highs?

The animal health leader continues to invest in its future.

Will Zoetis' Acquisition Spree Pay Off?

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #DrivenToCare--Zoetis today announced its long-term sustainability goals.

Zoetis Launches “Driven to Care” Sustainability Initiative and Long-Term Goals to Meet Commitments to Communities, Animals and the Planet

Zoetis Inc (NYSE: ZTS) seems well-positioned in 2021 with the stock valuation offering an attractive entry point, according to BofA Securities. The Zoetis Analyst: Michael Ryskin upgraded the rating for Zoetis from Neutral to Buy, while maintaining a price target of $180.

BofA Upgrades Zoetis Stock On Business Potential, Valuation

Agree Realty

Avis Budget Group

American Assets

Incyte

Molecular Templates

OPKO Health

Royalty Pharma

Sonos

United States Lime & Minerals, Inc.

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Returning buyers and chief executives were among the insiders making purchases this week.

The Past Week's Notable Insider Buys: Agree Realty, Avis Budget, Zoetis And More

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #fortune500--Zoetis will participate in the Cowen 41st Annual Health Care Conference on Monday, March 1, 2021.

Zoetis to Participate in the Cowen 41st Annual Health Care Conference

When it comes to stocks to buy, we are getting more selective, and that's a good thing. In fact, buying pressure in more selective stocks means they may have more profit potential going forward.

2 Fundamentally Superior Stocks I Just Rang the Register On

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. will participate in the Bank of America Securities 2021 Animal Health Summit Virtual Forum on Thursday, Feb. 25, 2021.

News for Zoetis Stock (ZTS)